These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25561879)

  • 1. Clinical biomarkers in sickle cell disease.
    Damanhouri GA; Jarullah J; Marouf S; Hindawi SI; Mushtaq G; Kamal MA
    Saudi J Biol Sci; 2015 Jan; 22(1):24-31. PubMed ID: 25561879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Biomarkers of Acute Vaso-Occlusive Sickle Cell Crisis.
    Khurana K; Mahajan S; Acharya S; Kumar S; Toshniwal S
    Cureus; 2024 Mar; 16(3):e56389. PubMed ID: 38633967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiology of Sickle Cell Disease.
    Sundd P; Gladwin MT; Novelli EM
    Annu Rev Pathol; 2019 Jan; 14():263-292. PubMed ID: 30332562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers in sickle cell disease.
    Rees DC; Gibson JS
    Br J Haematol; 2012 Feb; 156(4):433-45. PubMed ID: 22122125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sickle cell disease, vasculopathy, and therapeutics.
    Kassim AA; DeBaun MR
    Annu Rev Med; 2013; 64():451-66. PubMed ID: 23190149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathways to pulmonary hypertension in sickle cell disease: the search for prevention and early intervention.
    Shilo NR; Morris CR
    Expert Rev Hematol; 2017 Oct; 10(10):875-890. PubMed ID: 28817980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monocytosis is associated with hemolysis in sickle cell disease.
    Wongtong N; Jones S; Deng Y; Cai J; Ataga KI
    Hematology; 2015 Dec; 20(10):593-7. PubMed ID: 25875078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of blood rheology in sickle cell disease.
    Connes P; Alexy T; Detterich J; Romana M; Hardy-Dessources MD; Ballas SK
    Blood Rev; 2016 Mar; 30(2):111-8. PubMed ID: 26341565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term L-Glutamine Treatment Reduces Hemolysis without Ameliorating Hepatic Vaso-Occlusion and Liver Fibrosis in a Mouse Model of Sickle Cell Disease.
    Katoch O; Ungalara R; Kaminski T; Li Z; Dubey RK; Burholt I; Gudapati S; Pradhan-Sundd T
    Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation in Sickle Cell Disease: Differential and Down-Expressed Plasma Levels of Annexin A1 Protein.
    Torres LS; Okumura JV; Silva DG; Mimura KK; Belini-Júnior É; Oliveira RG; Lobo CL; Oliani SM; Bonini-Domingos CR
    PLoS One; 2016; 11(11):e0165833. PubMed ID: 27802331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fucosylation inhibitor, 2-fluorofucose, inhibits vaso-occlusion, leukocyte-endothelium interactions and NF-ĸB activation in transgenic sickle mice.
    Belcher JD; Chen C; Nguyen J; Abdulla F; Nguyen P; Nguyen M; Okeley NM; Benjamin DR; Senter PD; Vercellotti GM
    PLoS One; 2015; 10(2):e0117772. PubMed ID: 25706118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers for the central nervous system complications of sickle cell disease: are we there yet?
    Renella R
    Proteomics Clin Appl; 2021 Sep; 15(5):e2100026. PubMed ID: 34160906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel inflammatory role for platelets in sickle cell disease.
    Davila J; Manwani D; Vasovic L; Avanzi M; Uehlinger J; Ireland K; Mitchell WB
    Platelets; 2015; 26(8):726-9. PubMed ID: 25548984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current challenges in the management of patients with sickle cell disease - A report of the Italian experience.
    Russo G; De Franceschi L; Colombatti R; Rigano P; Perrotta S; Voi V; Palazzi G; Fidone C; Quota A; Graziadei G; Pietrangelo A; Pinto V; Ruffo GB; Sorrentino F; Venturelli D; Casale M; Ferrara F; Sainati L; Cappellini MD; Piga A; Maggio A; Forni GL
    Orphanet J Rare Dis; 2019 May; 14(1):120. PubMed ID: 31146777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced peripheral blood superoxide dismutase 2 expression in sickle cell disease.
    Armenis I; Kalotychou V; Tzanetea R; Moyssakis I; Anastasopoulou D; Pantos C; Konstantopoulos K; Rombos I
    Ann Hematol; 2019 Jul; 98(7):1561-1572. PubMed ID: 31098737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma PTX3 levels in sickle cell disease patients, during vaso occlusion and acute chest syndrome (data from Saudi population).
    Elshazly SA; Heiba NM; Abdelmageed WM
    Hematology; 2014 Jan; 19(1):52-9. PubMed ID: 23735470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sickle cell disease vasculopathy: a state of nitric oxide resistance.
    Wood KC; Hsu LL; Gladwin MT
    Free Radic Biol Med; 2008 Apr; 44(8):1506-28. PubMed ID: 18261470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate.
    Belcher JD; Chen C; Nguyen J; Zhang P; Abdulla F; Nguyen P; Killeen T; Xu P; O'Sullivan G; Nath KA; Vercellotti GM
    Antioxid Redox Signal; 2017 May; 26(14):748-762. PubMed ID: 26914345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative stress, antioxidant capacity, biomolecule damage, and inflammation symptoms of sickle cell disease in children.
    Biswal S; Rizwan H; Pal S; Sabnam S; Parida P; Pal A
    Hematology; 2019 Dec; 24(1):1-9. PubMed ID: 30010491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered red cell and platelet adhesion in hemolytic diseases: Hereditary spherocytosis, paroxysmal nocturnal hemoglobinuria and sickle cell disease.
    Sakamoto TM; Canalli AA; Traina F; Franco-Penteado CF; Gambero S; Saad ST; Conran N; Costa FF
    Clin Biochem; 2013 Dec; 46(18):1798-803. PubMed ID: 24060729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.